| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
49,160,000 |
| Market
Cap: |
369.19(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.14 - $13.81 |
|
| Level
I Sector: |
Financials |
| Level
II Sector: |
Financial Services |
| Level
III Sector: |
Diversified Investments |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Co.'s primary product candidate, pemvidutide (proposed INN), is a good laboratory practices-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis. In addition, Co. is developing HepTcell, an immunotherapeutic agent designed to achieve a functional cure for chronic hepatitis B.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
300 |
30,300 |
| Total Buy Value |
$0 |
$0 |
$863 |
$132,633 |
| Total People Bought |
0 |
0 |
1 |
3 |
| Total Buy Transactions |
0 |
0 |
1 |
5 |
| Total Shares Sold |
0 |
0 |
0 |
155,302 |
| Total Sell Value |
$0 |
$0 |
$0 |
$2,133,902 |
| Total People Sold |
0 |
0 |
0 |
5 |
| Total Sell Transactions |
0 |
0 |
0 |
9 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Schaffer Derace L |
Director |
– • – |
2011-08-24 |
4/A |
B |
$0.00 |
$0 |
D/D |
0 |
0 |
2.31 |
- |
|
| Schaffer Derace L |
Director |
– • – |
2011-08-24 |
4 |
B |
$0.70 |
$14,631 |
D/D |
20,902 |
1,038,613 |
2.39 |
- |
|
| Sayare Mitchel |
Director |
– • – |
2011-08-18 |
4 |
B |
$2.17 |
$10,850 |
D/D |
5,000 |
5,000 |
2.39 |
- |
|
| Runge Jeffrey W. |
Director |
– • – |
2011-06-17 |
4 |
B |
$2.69 |
$48,072 |
D/D |
17,850 |
17,850 |
2.39 |
- |
|
| Riddle Valerie D |
SVP, Medical Director |
• – – |
2011-05-31 |
4 |
AS |
$4.00 |
$35,222 |
D/D |
(8,792) |
44,436 |
|
- |
|
| Riddle Valerie D |
SVP, Medical Director |
• – – |
2011-05-31 |
4 |
OE |
$2.46 |
$8,457 |
D/D |
3,438 |
53,228 |
|
- |
|
| Riddle Valerie D |
SVP, Medical Director |
• – – |
2011-05-25 |
4 |
AS |
$3.75 |
$17,906 |
D/D |
(4,775) |
49,790 |
|
- |
|
| Riddle Valerie D |
SVP, Medical Director |
• – – |
2011-05-25 |
4 |
OE |
$2.96 |
$14,134 |
D/D |
4,775 |
54,565 |
|
- |
|
| Pappajohn John |
Director |
– • – |
2011-05-25 |
4 |
S |
$3.68 |
$184,135 |
I/I |
(50,000) |
394,044 |
|
- |
|
| Riddle Valerie D |
SVP, Medical Director |
• – – |
2011-05-23 |
4 |
AS |
$3.63 |
$32,082 |
D/D |
(8,791) |
49,790 |
|
- |
|
| Riddle Valerie D |
SVP, Medical Director |
• – – |
2011-05-23 |
4 |
OE |
$2.46 |
$8,457 |
D/D |
3,438 |
56,761 |
|
- |
|
| Schaffer Derace L |
Director |
– • – |
2011-05-19 |
4 |
S |
$3.68 |
$524,688 |
I/I |
(142,497) |
1,017,711 |
|
- |
|
| Schaffer Derace L |
Director |
– • – |
2011-05-18 |
4 |
S |
$3.68 |
$183,940 |
D/D |
(50,000) |
1,160,208 |
|
- |
|
| Schaffer Derace L |
Director |
– • – |
2011-05-17 |
4 |
S |
$3.71 |
$278,340 |
D/D |
(75,000) |
1,210,208 |
|
- |
|
| Richman Eric I |
See Remarks |
• • – |
2011-01-21 |
4 |
D |
$3.42 |
$10,455 |
D/D |
(3,057) |
109,822 |
|
- |
|
| Cook Francesca M |
VP, Policy & GVMNT Affairs |
• – – |
2011-01-21 |
4 |
D |
$3.42 |
$8,803 |
D/D |
(2,574) |
40,690 |
|
- |
|
| Riddle Valerie D |
VP, Medical Director |
• – – |
2011-01-21 |
4 |
D |
$3.42 |
$9,405 |
D/D |
(2,750) |
53,323 |
|
- |
|
| Richman Eric I |
See Remarks |
• • – |
2010-12-23 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
112,879 |
|
- |
|
| Schaffer Derace L |
Director |
– • – |
2010-11-24 |
4 |
OE |
$2.54 |
$1,128,582 |
D/D |
444,044 |
1,285,208 |
|
- |
|
| Pappajohn John |
Director |
– • – |
2010-11-22 |
4 |
OE |
$2.54 |
$1,128,582 |
I/I |
444,044 |
444,044 |
|
- |
|
| Mpm Asset Management Investors 2004 Bviii Llc |
10% Owner |
– – • |
2010-11-03 |
4 |
B |
$3.50 |
$1,505,000 |
I/I |
430,000 |
6,347,614 |
1.5 |
- |
|
| Mpm Asset Management Investors 2004 Bviii Llc |
10% Owner |
– – • |
2010-11-03 |
4 |
OE |
$2.54 |
$6,171,682 |
I/I |
2,428,171 |
5,917,614 |
|
- |
|
| Mccleary Joel |
Director |
– • – |
2010-11-03 |
4 |
OE |
$2.54 |
$47,675 |
D/D |
18,757 |
120,167 |
|
- |
|
| Richman Eric I |
President and CEO |
• • – |
2010-11-03 |
4 |
OE |
$2.54 |
$18,570 |
D/D |
7,306 |
77,879 |
|
- |
|
| Simon Nicholas J III |
10% Owner |
– – • |
2010-11-03 |
4 |
B |
$3.50 |
$1,505,000 |
I/I |
430,000 |
6,347,614 |
1.5 |
- |
|
417 Records found
|
|
Page 12 of 17 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.49 (6.98%) 
